… ProQR Update August 2022 Announced today (August 11, 2022), ProQR will focus exclusively on the development of the … from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 …
… Building an Inclusive ProQR At ProQR we strive to create an inclusive culture where everyone … logo to incorporate the pride rainbow flag. Pride month at ProQR is an opportunity to celebrate and thank all of the …
… ProQR update and additional sepofarsen Illuminate trial analyses ProQR has announced the completion of an in-depth strategic … additional analyses of the sepofarsen *Illuminate* trial. ProQR has announced the completion of an in-depth strategic …
In June we caught up with our Lead Talent Acquisition, Silvia Catellani, to talk about ProQR, Pride, and driving an inclusive culture for present and future ProQRians.
This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
… ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology LEIDEN, the Netherlands, Jan. 08, … fibrosis targets,” said Daniel A. de Boer, CEO of ProQR. “We look forward to working closely with the team at …
